Key Drivers
- Strong liquidity
- High cash burn
- Stretched valuation
AIAI Summary
TSHA has shifted from long‑term R&D to a near‑term, binary investment driven by the REVEAL pivotal dosing completion and a potential 6‑month interim that could support a BLA, which could sharply re‑rate the stock if clinical and PPQ execution succeed. Monitor enrollment/timeline adherence, PPQ/CMC milestones, and signs of non‑dilutive funding closely—any delay, manufacturing hiccup, or need to raise equity at weak terms would materially amplify downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High cash burn
- •Stretched valuation
TSHA has a strong balance sheet and ample near-term liquidity (cash ≈24.6% of market cap, current ratio 12.2) but faces persistent operating losses, ~3.5 years of cash runway at current burn, and stretched valuation multiples.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Tight range
- •Support band
Modest downtrend last month with lower highs and a move from $4.70 to $4.40 (≈‑6.4%) within a tight $4.40–$4.89 range, supported around $4.49–$4.57 and vulnerable to further selling absent a catalyst.
Drift to the period low $4.40 on 2026-03-20 indicates renewed selling pressure
Sentiment & News
Key News Insights:
- •Executive grant
- •Ally Bridge stake
- •REVEAL dosing progress
Taysha disclosed an executive equity inducement, saw Ally Bridge build a 3.8% stake, and reported dosing progress in the pivotal TSHA‑102 Rett trial with enrollment and dosing on track to complete in Q2 2026.
Combined governance clarity, new institutional ownership, and advancing pivotal trial dosing should bolster investor confidence and help de‑risk near‑term clinical milestones
Similar Companies in Healthcare
Other companies in the same sector with AI ratings